Inventiva SA
PAR:IVA
Inventiva SA
Total Current Liabilities
Inventiva SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€48.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€114.6m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
23%
|
CAGR 10-Years
16%
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Current Liabilities
€56.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
35%
|
CAGR 10-Years
34%
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Current Liabilities
€33m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
12%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€36.4m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
10%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Current Liabilities
€54.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
19%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Total Current Liabilities?
Total Current Liabilities
48.1m
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Total Current Liabilities amounts to 48.1m EUR.
What is Inventiva SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
28%
Over the last year, the Total Current Liabilities growth was -4%. The average annual Total Current Liabilities growth rates for Inventiva SA have been 28% over the past three years , 28% over the past five years .
You don't have any saved screeners yet